Antiretroviral
Also known as ATZ, ritonavir-boosted atazanavir
Atazanavir is an antiretroviral protease inhibitor that specifically targets the HIV-1 protease enzyme. It competitively binds to the active site of HIV-1 protease, preventing the cleavage of viral gag-pol polyproteins into their functional components. This inhibition leads to the production of immature, non-infectious viral particles, thereby disrupting the viral life cycle and reducing the viral load in HIV-infected patients.
Manufacturer advises avoid —toxicity in animal studies.
Manufacturer advises avoid —present in milk in animal studies.
Substantially reduced atazanavir concentrations, leading to loss of antiviral effectiveness.
Proton pump inhibitors should be avoided in patients receiving atazanavir without ritonavir.
Source: G&G 14e · p1245-1266
Reduced atazanavir concentrations, leading to loss of antiviral effectiveness.
H2 receptor antagonists should be avoided in patients receiving atazanavir without ritonavir.
Source: G&G 14e · p1245-1266
Substantially reduced atazanavir concentrations, leading to loss of antiviral effectiveness.
Proton pump inhibitors should be avoided in patients receiving atazanavir without ritonavir.
Source: G&G 14e · p1245-1266
Substantially reduced atazanavir concentrations, leading to loss of antiviral effectiveness.
Proton pump inhibitors should be avoided in patients receiving atazanavir without ritonavir.
Source: G&G 14e · p1245-1266
Substantially reduced atazanavir concentrations, leading to loss of antiviral effectiveness.
Proton pump inhibitors should be avoided in patients receiving atazanavir without ritonavir.
Source: G&G 14e · p1245-1266
Significantly reduced atazanavir concentrations, leading to loss of antiviral effectiveness.
Contraindicated.
Source: G&G 14e · p1245-1266
Increased risk of rhabdomyolysis and myopathy.
Avoid concurrent use; if needed, use lowest statin dose
Source: KDT 7e · p948
Carbamazepine toxicity (diplopia, ataxia, drowsiness)
Avoid concurrent use or adjust dose with monitoring
Source: KDT 7e · p948
Nephrotoxicity and immunosuppression toxicity
Monitor cyclosporine levels and reduce dose
Source: KDT 7e · p948
Hypoglycemia.
Avoid concurrent use or adjust dose
Source: KDT 7e · p948
Hypoglycemia
Avoid concurrent use or adjust dose
Source: KDT 7e · p948
Hypoglycemia
Avoid concurrent use or adjust dose
Source: KDT 7e · p948
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team